pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Baseline characteristics of all subjects

Potential drug-drug interaction Total p-value

Y (n=479) N (n=582) (n=1061)
Age [years]
≥ 65 357(75%) 411(71%) 768(72%) 0.156
< 65 122(25%) 171(29%) 293(28%)

Gender
Male 270(56%) 285(49%) 555(52%) 0.016
Female 209(44%) 297(51%) 506(48%)
Duration [days]
median(IQR) 12 (6-25) 13 (5-24) 12 (6-27) 0.272

Indication
Hyperlipidemia 314(66%) 416(71%) 730(69%) 0.000
Myocardial infarction 89(19%) 51(9%) 140(13%)
Cerebral infarction 32(7%) 68(12%) 100(9%)
Angina pectoris 43(9%) 41(7%) 84(8%)
Post operation 1(0%) 6(1%) 7(1%)

Comorbidity
Hypertension 225(47%) 272(47%) 497(47%) 0.011
Diabetes mellitus 106(22%) 142(24%) 248(23%)
Arrhythmia or heart failure 15(3%) 3(1%) 18(2%)
Others 133(28%) 165(28%) 298(28%)

AST [IU/L]
>40 109(23%) 70(12%) 179(17%) 0.000
≤40 370(77%) 512(88%) 882(83%)

ALT [IU/L]
>40 105(22%) 71(12%) 176(17%) 0.000
≤40 374(78%) 511(88%) 885(83%)

IQR (Interquartile Range); AST (aspartate aminotransferase); ALT (alanine aminotransferase)

Korean J Clin Pharm 2020;30:31-5 https://doi.org/10.24304/kjcp.2020.30.1.31
© 2020 Korean J Clin Pharm